Contineum Therapeutics (CTNM) investor relations material

Key accomplishments and clinical progress

• Executed four clinical studies in the first full year as a public company, including a phase 1b PET receptor occupancy study for PIPE-791 and full enrollment of a phase 1b exploratory study in chronic pain, with data expected in the first half of next year.

• Reported VISTA data for PIPE-307 in relapsing-remitting MS, missing the primary endpoint but gaining valuable insights into M1 receptor antagonism.

• Preparing to launch a phase 2 proof-of-concept study in idiopathic pulmonary fibrosis (IPF) with PIPE-791, designed to be operationally similar to a phase 3 trial.

Scientific rationale and differentiation

• LPA1 receptor antagonism targets fibrosis and inflammation in IPF, chronic pain, and progressive MS by inhibiting fibroblast recruitment and neuroinflammation.

• PIPE-791 offers once-daily dosing, high receptor occupancy (>90%), and a favorable safety profile compared to competitors, notably BMS’s BID regimen and hypotension signals.

• Preclinical and human tissue studies demonstrated reduced fibrosis markers and LPA1 expression in IPF, supporting clinical development.

Market landscape and opportunity

• Current IPF treatments have significant tolerability issues, leading to high discontinuation rates and an unmet need for safer, more effective therapies.

• The IPF market remains largely untapped, with existing drugs generating over $4 billion in annual sales despite their limitations.

• LPA1 antagonists are positioned to become the backbone of future IPF and PPF therapies, with potential for combination regimens.